Prognostic meaning of tissue inhibitors of matrix metalloproteinases TIMP-1 and TIMP-2 in patients with colorectal cancer-Reference-Cited by-同舟云学术

Prognostic meaning of tissue inhibitors of matrix metalloproteinases TIMP-1 and TIMP-2 in patients with colorectal cancer

Published:2020 Issue:1 Volume:66 Page:25-32
ISSN:1857-8969
Container-title:Macedonian Pharmaceutical Bulletin
language:en
Short-container-title:Maced. Pharm. Bull.

Author:

Kostova Elena¹,Shubeska Stratrova Slavica²

Affiliation:

1. Department of Preclinical and Clinical Pharmacology and Toxicology, Medical Faculty, Ss. Cyril and Methodius University, 50 Divizija 6,1000 Skopje, Republic of North Macedonia

2. University Clinic of Endocrinology, Diabetes and Metabolic disorders, Medical Faculty, Ss. Cyril and Methodius University, Mother Theresa 17, 1000 Skopje, Republic of North Macedonia

Abstract

The aim of this study was to analyze TIMP-1 and TIMP-2 serum levels in patients with colorectal cancer (CRC) and to correlate the results with the pathological stage of the disease and outcome in order to evaluate the role of TIMP-1 and TIMP-2 serum levels as prognostic markers. The investigation has been made on 82 patients with operable CRC without distant metastases, who had undergone blood tests in order to determine the TIMP-1 and TIMP-2 serum levels in the following points of time: preoperatively, as well as 3, 6, 9 and 12 months postoperatively. Significant differences were found between serum levels of TIMP-1 and TIMP-2 obtained preoperatively and postoperatively, as well as significant association of serum TIMP-1 levels obtained preoperatively in CRC patients in stage I and III, in the 3th and in the 6th month (p<0.001) postoperatively as defined points of time with the outcome of CRC patients. Serum TIMP-2 levels obtained preoperatively was significantly associated with the outcome of the CRC patients. Analysis of the obtained TIMP-1 and TIMP-2 serum levels in CRC patients showed statistically significant differences with: disease progression, occurrence of liver metastasis, prior to and post chemotherapy treatment. The results derived a conclusion that the serum levels of TIMP-1 and TIMP-2 could be indicators for occurrence and progression of CRC, as well as valuable and useful markers for following the effects of chemotherapy treatment. Keywords: colorectal cancer, TIMP-1, TIMP-2, prognosis

Publisher

Macedonian Pharmaceutical Association

Subject

General Medicine

Link

http://bulletin.mfd.org.mk/volumes/Volume%2066_1/66_1_002.pdf

Reference25 articles.

1. Albini, A., Melchiori, A., Santi, L., Liotta, L.A., Brown, P.D., Stetler-Stevenson, W.G., 1991. Tumor cell invasion inhibited by TIMP-2. J. Nat. Cancer Inst. 83, 775-779. Available at: https://doi.org/10.1093/jnci/83.11.775.

2. Amour,A., Slocombe, P.M., Webster, A., Butler, M., Knight, C.G., Smith, B.J., Stephens, P.E., Shelley, C., Hut¬ton, M., Knauper, V., Docherty, A.J., Murphy, G., 1998. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 435, 39-44. Available at: https://doi.org/10.1016/S0014-5793(98)01031-X.

3. Baker A.H., Zaltsman A.B., George S.J., Newby A.C., 1998. Divergent effects of tissue inhibitor of metallopro¬teinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J. Clin. Invest. 101, 1478-1487. Available at: https://doi.org/10.1172/JCI1584.

4. Brand, K., Baker, A.H., Perez-Canto, A., Possling, A., Sacharjat, M., Geheeb, M., Arnold, W., 2000. Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue. Cancer Res. 60, 5723-5730.

5. Chesler, L., Golde, D.W., Bersch,N., Johnson, M.D., 1995. Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1. Blood 86, 4506–4515. Available at: https://doi.org/10.1182/blood.V86.12.4506.bloodjournal86124506.